High-dose-rate brachytherapy combined with long-term hormonal therapy for high-risk prostate cancer: Results of a retrospective analysis

2006 ◽  
Vol 24 (1) ◽  
pp. 58-64 ◽  
Author(s):  
Ryoong-Jin Oh ◽  
Yasuo Yoshioka ◽  
Eiichi Tanaka ◽  
Hiroya Shiomi ◽  
Iori Sumida ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Dose Rate ◽  
Retrospective Analysis ◽  
Hormonal Therapy ◽  
High Dose Rate ◽  
High Dose ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer

Long-term outcomes of high-dose-rate brachytherapy for intermediate- and high-risk prostate cancer with a median follow-up of 10 years

2016 ◽  
Vol 120 (1) ◽  
pp. 56-60 ◽  
Author(s):  
John W. Yaxley ◽  
Kevin Lah ◽  
Julian P. Yaxley ◽  
Robert A. Gardiner ◽  
Hema Samaratunga ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Dose Rate ◽  
High Dose Rate ◽  
High Dose ◽  
Long Term Outcomes ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer

Twice vs Single Applications in High Dose Rate Brachytherapy (HDR) Boost. Same Results in High Risk Prostate Cancer Patients?

Brachytherapy ◽  
2017 ◽  
Vol 16 (3) ◽  
pp. S114
Author(s):  
Silvia Rodriguez Villalba ◽  
Antonio Otal Palacin ◽  
Jose Richart Sancho ◽  
Jose Perez-Calatayud ◽  
Manuel Santos Ortega ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Dose Rate ◽  
Cancer Patients ◽  
High Dose Rate ◽  
High Dose ◽  
High Dose Rate Brachytherapy ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer

scholarly journals Prostate-specific antigen nadir after high-dose-rate brachytherapy predicts long-term survival outcomes in high-risk prostate cancer

2016 ◽  
Vol 2 ◽  
pp. 95-103 ◽  
Author(s):  
Hideyasu Tsumura ◽  
Takefumi Satoh ◽  
Hiromichi Ishiyama ◽  
Ken-ichi Tabata ◽  
Shouko Komori ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Specific Antigen ◽  
High Dose Rate ◽  
Survival Outcomes ◽  
High Dose ◽  
Term Survival ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer
Sign in / Sign up

Export Citation Format

Share Document